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The Lack of Cardiovascular Risk Factor Management in Patients with
Critical Limb Ischaemia∗
J. Bismuth†, L. Klitfod and H. Sillesen
Department of Vascular Surgery, Gentofte Hospital, University of Copenhagen, Denmark
Aim: to define the level of management of cardiovascular risk factors in patients treated for critical limb ischaemia in a
vascular surgical setting.
Materials and Methods: retrospective review of all (n=147) patients operated on for critical lower extremity ischaemia
in 1998. We included pre- and postoperative cardiac events.
Results: only eight (5%) (95% CI; 2–9) were on lipid lowering treatment and 58 (39%) (95% CI; 31–47) using
acetylsalicylic acid.
Conclusions: only a minority of patients operated on for CLI were receiving adequate cardiovascular risk factor
modification.
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Introduction (46–93) years. Mortality data was obtained from the
Civil Registry. The median follow-up was 1.5 years.
Fifty percent of patients operated on for critical limb Risk factor analysis included recording of age, smok-
ing status, diabetes, cerebrovascular events, hyper-ischaemia (CLI) die within 5 years,1–3 mainly due to
cardiovascular events.4–6 There is ample evidence that tension, cardiac events pre- and postoperatively, and
ECG findings. Furthermore, intake of medicine onlipid lowering with statins is indicated in patients
with symptomatic coronary artery disease (CAD).7–9 admission, date of operation, and date of death were
recorded. All variables were recorded in a database,However, the evidence for patients with peripheral
artery disease is weaker.10–14 Yet the majority of patients and statistical analyses, including survival analysis
(Kaplan–Meier method), were performed using thewith CLI have CAD and in at least a third this is
symptomatic. Our impression, nevertheless, is that this statistical software SPSS 10.0 (SPSS Inc., Chicago,
Illinois, U.S.A.). Confidence intervals (CI) were cal-patient group is not being treated with statins. The
aim of this retrospective study was to document the culated at the 95% level. p-values were calculated
using the Log-rank test, and statistical significance wasmanagement of cardiovascular risk factor in patients
operated for CLI. taken as p<0.05.
Results
Patients and Methods
Risk factors and co-morbidity are recorded in Tables
This was a retrospective case note review of 147 1 and 2. Only eight (5%) (95% CI; 2–9) patients had
patients operated on for CLI during 1998. There were been prescribed statins (Table 3); three of whom had
82 males and 65 females of median (range) age 76 documented CAD. Merely three of 46 (7%) patients
with documented CAD had been prescribed a statin.
Only 58 patients (39%) (95% CI; 31–47) were on aspirin.
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Table 1. Preoperative risk factor analysis. The number of patients for each respective risk factor (age >70, diabetes, smoking,
hypertension, stroke/TIA, and disease in three vascular beds) is listed, as well as the percentage of those who died during the study
period. p-values are based on the Log-rank test.
Risk factor Total n=147 (%) Death rate Mean survival (95% CI) p
(days) (Log-rank)
Age >70 years 98 (67%) 37 (38%) 586 (532–640) 0.0079
Age <70 years 49 (33%) 7 (14%) 692 (631–752)
Diabetes 38 (26%) 12 (32%) — — NS
Dietary control 8 (5%) 4 (50%) — —
Oral medication 19 (13%) 4 (21%) — —
Insulin adult onset 8 (5%) 2 (25%) — —
Insulin juvenile onset 3 (2%) 2 (67%) — —
Smoking 112 (76%) 25 (22%) 0.0171
Never smoked 35 (24%) 650 (595–704)
Previous smokers 31 (21%) 644 (554–732)
Current smokers 81 (55%) 533 (447–619)
Hypertension 96 (65%) 30 (31%) — — NS
1 antihypertensive 47 (32%) — —
2 antihypertensives 37 (25%) — —
>3 antihypertensives 11 (7%) — —
Untreated 1 (1%) — —
Cerebrovascular events 25 (17%) 12 (48%) 0.0012
No symptoms 122 (83%) 638 (595–680)
Amaurosis fugax/TIA 5 (3%) 276 (138–414)
Stroke 20 (14%) 551 (419–684)
Disease in three vascular 10 (7%) 8 (80%) 0.0003
beds
One bed 74 (50%) 14 (19%) 672 (623–722)
Two beds 63 (43%) 22 (35%) 602 (539–666)
Three beds 10 (7%) 8 (80%) 294 (124–463)
PAD=peripheral arterial disease; TIA=transient ischaemic attack; NS=not significant; CI=confidence intervals.
Table 2. Preoperative cardiac events. The number of patients for each respective cardiac event (angina pectoris, acute myocardial
infarction, congestive heart failure, previous CABG, arrhythmia) is listed, as well as which percentage of each died during the study
period. The totals calculated for ischaemic heart disease and all cardiac events are not simply an addition of all events as in some
cases patients had more than one manifestation of cardiac disease. p-values are based on the Log-rank test.
Event Total n=147 (%) Death rate Mean survival (days) (95% CI) p
(Log-rank)
Angina pectoris 21 (14.3%) 9 (43%) — — NS
Stable 20 (14%)
Unstable 1 (0.7%)
Acute Myocardial Infarction 25 (17%) 9 (36%) — — NS
>6 months prior to surgery 8 (5%)
<6 months prior to surgery 17 (12%)
Coronary artery bypass graft/ 3 (2%) 2 (67%) — — —
percutaneous transluminal
angioplasty
Total with IHD 46 (31%) 18 (39%) 548 (459–638) 0.0243
CHF 18 (12%) 8 (44%) — — NS
Arrhythmia 37 (25%) 16 (43%) 550 (456–644) 0.0383
All cardiac disease 66 (45%) 27 (41%) 560 (490–630) 0.0101
IHD=ischaemic heart disease; CHF=congestive heart failure; NS=not significant; CI=confidence intervals.
arteriosclerosis in three vascular beds (lower extremity, Discussion
cerebrovascular, coronary) and mortality rate (p=
0.0003) (Table 1), using the Log-rank test for com- Despite the existence of a considerable evidence base16,17
only a minority of patients operated on for CLI, andparison of survival rates in patients with events 1, 2
or 3 vascular beds. with documented CAD, were receiving a statin or aspirin.
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Table 3. Registration of cardiac medications at admission. The number of
patients using each medication is listed, as well as 95% confidence intervals.
Medication Total n=147 (%) (95% CI)
Statin 8 (5%) (2–9)
Acetylsalicylic acid (ASA) 58 (39%) (31–47)
Beta-blocker 17 (12%) (6–17)
ACE-inhibitor 28 (19%) (13–25)
ACE-inhibitor/diabetes 10 (7%) (3–12)
Coumarin 12 (8%) (4–13)
ACE=angiotensin converting enzyme; CI=confidence intervals.
medical, as well as the surgical, management of their
patients.
References
1 Whittemore AD. Infrainguinal bypass. In: Rutherford RB. Vas-
cular Surgery. W.B. Saunders Company, Philadelphia 1995,
pp. 794–814.
2 Dawson I, van Bockel JH, Brand R. Late nonfatal and fatal
0 2
100
Time (years)
95%
%
 S
u
rv
iv
al
80
60
40
20
1.510.5
22
Pts at risk
147 118
95%
Background pop.
cardiac events after infrainguinal bypass for femoropopliteal
Fig. 1. Cumulative survival rate for entire patient material, with occlusive disease during a thirty-one-year period. Journal of
95% confidence intervals. An age and sex matched population is Vascular Surgery 1993; 18: 249–260.
depicted as a dashed line (–––) for comparison. Patients at risk are 3 Criqui MH, Langer RD, Fronek A et al. Mortality over a period
noted above the x-axis. of 10 years in patients with peripheral arterial disease. New
England Journal of Medicine 1992; 326: 381–386.
4 Leng GC, Lee AJ, Fowkes FGR et al. Incidence, natural history
and cardiovascular events in symptomatic and asymptomaticFurthermore, a systematic review of current lit-
peripheral arterial disease in the general population. Internationalerature suggests that lipid lowering treatment in
Journal of Epidemiology 1996; 25: 1172–1181.patients with lower extremity ischaemia not only re- 5 Newman AB, Siscovick DS, Manolio TA et al. Ankle–arm index
as a marker of atherosclerosis in the cardiovascular health study.duces mortality, but also slows progression of the
Circulation 1993; 88: 837–845.peripheral atherosclerotic disease.11 Unfortunately, this
6 Hertzer NR, Beven EG, Young JR et al. Coronary artery diseasereview is based on seven small randomised controlled in peripheral vascular patients. A classification of 1000 coronary
angiograms and results of surgical management. Annals of Sur-studies, and must therefore be interpreted with cau-
gery 1984; 199: 223–233.tion. To date, no large-scale controlled randomised
7 Scandinavian Simvastatin Survival Study Group. Ran-trials have been conducted in this patient population. domised trial of cholesterol lowering in 4444 patients with
coronary heart disease: the Scandinavian Simvastatin SurvivalThis preventive management is supported by the Re-
Study (4S). Lancet 1994; 344: 1383–1389.commendations of the Second Joint Task Force of
8 Ridker PM, Rifai N, Pfeffer MA et al. Inflammation, pravastatin,European and other Societies on Coronary Prevention, and the risk of coronary events after myocardial infarction in
patient with average cholesterol levels. Cholesterol and Re-published in 1998, stating that the treatment level for
current Events Investigators. Circulation 1998; 98: 839–844.patients with PVD should parallel that for CAD.20
9 The LIPID Study Group. Prevention of cardiovascular eventsSince 1998 there has been increased interest in and death with pravastatin in patients with coronary heart
disease and a broad range of initial cholesterol levels. N Engl Jcardiovascular risk factor reduction in patients with
Med 1998; 339: 1349–1357.peripheral vascular disease (PVD)18 including lifestyle
10 Blankenhorn DH, Johnson RL, Nessim SA et al. The Cho-changes (smoking cessation, healthy diet and increased lesterol Lowering Atherosclerosis Study (CLAS): Design,
methods and baseline results. Controlled Clinical Trials 1987; 8:physical activity), factors such as blood pressure, blood
356–387.glucose and lipids require active medical management.
11 Leng GC, Price JF, Jepson RG. Lipid-lowering pharmacotherapy forThe present study has also indicated that only a lower limb atherosclerosis. The Cochrane Library.
12 Blankenhorn DH, Azen SP, Crawford DW et al. Effects ofminority of patients were being treated with aspirin:
colestipol–niacin on human femoral atherosclerosis. Circulationagain, despite overwhelming evidence supporting its
1991; 83: 438–447.benefit.21 13 Duffield RGM, Miller NE, Brunt JNH et al. Treatment of
hyperlipidaemia retards progression of symptomatic femoralIn order to optimise treatment in our department,
atherosclerosis. Lancet 1983; 2: 639–644.we now screen all our patients for hyperlipidaemia
14 Nye ER, Macbeth WAAG. The treatment of intermittent clau-and institute statin treatment where appropriate. dication with beta-pyridyl carbinol over two years. Atherosclerosis
1973; 17: 95–106.Vascular surgeons must take responsibility for the
Eur J Vasc Endovasc Surg Vol 21, February 2001
J. Bismuth et al.146
15 Clark AL, Byrne JC, Nasser A, McGroarty E, Kennedy JA. 19 Antiplatelet Trialists’ Collaboration. Collaborative over-
view of randomised trials of antiplatelet therapy-I: PreventionCholesterol in peripheral vascular disease – a suitable case for
of death, myocardial infarction, and stroke by prolonged anti-treatment? Quarterly Journal of Medicine 1999; 92: 219–222.
platelet therapy in various categories of patients. British Medical16 Shepherd J, Cobbe SM, Ford I et al., for the West of Scotland
Journal 1994; 308: 81–106.Coronary Prevention Study Group (WOSCOP). Prevention of
20 Wood D, De Backer G, Faergeman O, Graham I, Mancia G,coronary artery disease with pravastatin in men with hyper-
Pyorala K. Prevention of coronary heart disease in clinicalcholesterolaemia. N Engl J Med 1995; 333: 1301–1307.
practice. Recommendations of the Second Joint Task Force of17 Downs JR, Clearfield M, Weis S et al., for the AFCAPS/
European and other Societies on Coronary Prevention. Eur HeartTexCAPS Research Group. Primary prevention of acute coronary
J 1998; 19: 1434–1503.events with lovastatin in men and women with average cho- 21 McDermott MM, Mehta S, Ahn H, Greenland P. Athero-
lesterol levels. JAMA 1998; 279: 1615–1622. sclerotic risk factors are less intensely treated in patients with
18 Wood D, De Backer G, Faergeman O et al. Prevention of peripheral arterial disease than in patients with coronary artery
coronary heart disease in clinical practice: Recommendations of disease. J Gen Intern Med 1997; 12: 209–215.
the Second Joint Task Force of European and other Societies on
Coronary Prevention. Eur Heart J 1998; 19: 1434–1503. Accepted 4 December 2000
Eur J Vasc Endovasc Surg Vol 21, February 2001
